Project III: Vitamin D Concentrations, Genetic Modifiers, and Parkinson Disease Parkinson disease (PD) results from genetic and environmental factors and complex interactions between them. Basic science, epidemiology and genetic studies have accumulated evidence supporting a role of vitamin D (vit D) in PD susceptibility. In addition to vit D providing neuroprotection for dopaminergic neurons, low vit D concentrations are more common in and increase risk of PD. Also, vitamin D receptor (VDR) gene polymorphisms appear to modulate risk for and age at onset of PD. However, these VDR polymorphism effects on PD risk vary in different study populations. One explanation is that genetic effects are dependent on 'exposure'to vit D, which varies across populations. For example, in osteoporosis, genetic factors modulate the apparent protective effects of vit D. Because vit D concentration is largely determined by diet and sunlight exposure, vit D blood concentration is modifiable. Vit D supplementation is a potential therapeutic strategy if the link between vit D and PD can be confirmed and better understood. We will jointly analyze the effects of environmental exposure (25-hydroxy-vitamin D (25[OH]D) concentration from blood plasma samples) and the common genetic variants on risk and age at onset of PD. Built on the previous epidemiologic and genetic studies, this study will also provide valuable insights on a gene-environment interaction that may play an important role in PD pathogenesis. Importantly, results of the study will guide future efforts to determine if vit D supplementation can treat or prevent PD, and if people with a certain genetic makeup benefit more from vit D supplementation than others. We hypothesize that plasma vit D concentration modifies the genetic effects of vit D-related genes and that genetic factors modify the effect of vit D on the risk of developing PD. To test our hypothesis, we have developed three specific aims: 1) Evaluate the association of plasma vit D level and risk and age at onset of PD in three case-control samples. 2) Conduct analysis to identify potential vit D-gene interactions underlying PD risk or age at onset. 3) Thoroughly examine vit D-associated genes for functional variants that explain their associations with PD.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Specialized Center (P50)
Project #
5P50NS071674-05
Application #
8740569
Study Section
Special Emphasis Panel (ZNS1-SRB-E)
Project Start
Project End
Budget Start
2014-09-01
Budget End
2015-08-31
Support Year
5
Fiscal Year
2014
Total Cost
$186,145
Indirect Cost
$64,482
Name
University of Miami School of Medicine
Department
Type
DUNS #
052780918
City
Coral Gables
State
FL
Country
United States
Zip Code
33146
Rawlik, Konrad; Rowlatt, Amy; Tenesa, Albert (2016) Imputation of DNA Methylation Levels in the Brain Implicates a Risk Factor for Parkinson's Disease. Genetics 204:771-781
Lubbe, Steven J; Escott-Price, Valentina; Brice, Alexis et al. (2016) Is the MC1R variant p.R160W associated with Parkinson's? Ann Neurol 79:159-61
Nuytemans, Karen; Maldonado, Lizmarie; Ali, Aleena et al. (2016) Overlap between Parkinson disease and Alzheimer disease in ABCA7 functional variants. Neurol Genet 2:e44
El Hokayem, Jimmy; Cukier, Holly N; Dykxhoorn, Derek M (2016) Blood Derived Induced Pluripotent Stem Cells (iPSCs): Benefits, Challenges and the Road Ahead. J Alzheimers Dis Parkinsonism 6:
Esanov, Rustam; Belle, Kinsley C; van Blitterswijk, Marka et al. (2016) C9orf72 promoter hypermethylation is reduced while hydroxymethylation is acquired during reprogramming of ALS patient cells. Exp Neurol 277:171-7
Lubbe, S J; Escott-Price, V; Brice, A et al. (2016) Rare variants analysis of cutaneous malignant melanoma genes in Parkinson's disease. Neurobiol Aging 48:222.e1-222.e7
Hossein-Nezhad, Arash; Fatemi, Roya Pedram; Ahmad, Rili et al. (2016) Transcriptomic Profiling of Extracellular RNAs Present in Cerebrospinal Fluid Identifies Differentially Expressed Transcripts in Parkinson's Disease. J Parkinsons Dis 6:109-17
Xiong, Nian; Li, Nuomin; Martin, Eden et al. (2016) hVMAT2: A Target of Individualized Medication for Parkinson's Disease. Neurotherapeutics 13:623-34
Zeier, Zane; Esanov, Rustam; Belle, Kinsley C et al. (2015) Bromodomain inhibitors regulate the C9ORF72 locus in ALS. Exp Neurol 271:241-50
Pastori, Chiara; Kapranov, Philipp; Penas, Clara et al. (2015) The Bromodomain protein BRD4 controls HOTAIR, a long noncoding RNA essential for glioblastoma proliferation. Proc Natl Acad Sci U S A 112:8326-31

Showing the most recent 10 out of 28 publications